Is Tesamorelin legal in Denmark?

Tesamorelin is among the peptides readers most often ask about in Denmark. This page focuses on the regulatory reality there, not on how to obtain or use it, because that is where reliable, localized information is hardest to find.

In Denmark, Tesamorelin has no marketing authorisation. It is FDA-approved in the United States (as Egrifta), but the European marketing-authorisation application was withdrawn in 2012, so there is no authorised tesamorelin product in Denmark. It is an unlicensed medicine here.

Because there is no marketing authorisation, Tesamorelin can only be supplied as an unlicensed medicine, via a named-patient or “specials” import that a prescriber requests and takes responsibility for. General or online sale to the public is not lawful, and customs may detain unauthorised shipments. There is no ordinary lawful consumer route in Denmark. Any legitimate access runs through the unlicensed-medicine / named-patient framework overseen by Lægemiddelstyrelsen (Danish Medicines Agency).

Selling or supplying Tesamorelin without the required authorisation is an offence in Denmark. Lægemiddelstyrelsen (Danish Medicines Agency) sets out the applicable sanctions; we do not reproduce specific figures here because they change. Confirm the current penalties with the regulator. This page reflects our reading of the position as of the last-verified date; regulations change, so confirm with Lægemiddelstyrelsen (Danish Medicines Agency) before making any decision.